Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia;Metaloproteinazy macierzy zewna̧trzkomórkowej MMP-2 i MMP-9 oraz tkankowe Inhibitory TIMP-1 i TIMP-2 w osoczu dzieci chorych na ostra̧ białaczkȩ limfoblastyczna̧

Polski Merkuriusz Lekarski

Volumn 29, Issue 169, 2010, Pages 14-18

  Krawczuk Rybak, Maryna ^a   Kuźmicz, Marta ^a   Mroczko, Barbara ^a   Szmitkowski, MacIej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acute lymphoblastic leukemia; Children; Matrix metalloproteinases; Tissue inhibitor of matrix metalloproteinases

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD; CHILD; HUMAN; INFANT; PRESCHOOL CHILD; REFERENCE VALUE;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REFERENCE VALUES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 77955949153     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Citak E.C., Oguz A., Karadeniz C: Role of gelatinases (MMP-2 AND MMP-9), TIMP-1, Vascular Endothelial Growth Factor (VEGF), and microvessel density on the clinicopathological behavior of childhood non-Hodgkin Lymphoma. Ped. Hematol. Oncol., 2008, 25, 55-66.
2. Gong J., Zhao Y., Abdel-Fattah R. I wsp.: Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary, 2008, 11, 37-48.
3. Hoikkala S., Paakko P., Soini Y. i wsp.: Tissue MMP-2 and MMP-9 [corrected] are Belter prognostic factors than serum MMP-2/TIMP-2 - complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. Cancer Lett., 2006, 236, 125-132.
4. Jaworska-Wieczorek A., Marquez L.A., Matsuzaki A. I wsp.: Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitor sof metalloproteinases (TIMP-1 and -2) in acute myelogenous leukemia blasts: comparison with normal bone marrow cells. Br. J. Hemat., 1999, 105, 402-411.
5. Klein G., Vellenga E., Fraaije M.W. i wsp.: The possibile role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol., 2004, 50, 87-100.
6. Kuittinen O.: Matrix metalloprołeinase-2 (MMP-2) and -9 (MMP-9) in hematological malignancies. Oulu University Library, 2002.
7. Kuittinen O., Savolainen E.R., Koistinen P. i wsp.: MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk. Res., 2001, 25, 125-132.
8. Kornaszewska A., Urbaniak J., Nowicka J., Woźniak M.: Aktywność zelatynaz i stȩżenie elastazy granulocytów w osoczu chorych na ostra̧ białaczkȩ nielimfoblastyczna̧ i na przewlekła̧ białaczkȩ szpikowa̧. Adv. Clin. Exp. Med., 2003, 12, 289-295.
9. Lambert E., Bridoux L., Devy J. i wsp.: TIMP-1 binding to proMMP-9/ CD44 complex localized at the cell surface promotes erythroid cell survival. Int. J. Bioch. Biol., 2009, 41, 1102-1115.
10. Lin L.I., Lin D.T., Chang C.J. i wsp.: Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukemia. Br. J. Hematol., 2002, 17, 835-841.
11. Melamed D., Messika O., Glass-Marmor L., Miller A.: Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. Int. Immunol., 2006, 18, 1355-1362.
12. Mroczko B., Groblewska M., Łukaszewicz-Zaja̧c M. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clin. Chem. Lab. Med., 2009, 47, 1133-1139.
13. Negaard H., Svennevig K., Kolset S.O. i wsp.: Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. Leuk. Lymph., 2009, 50, 998-1004.
14. Pegahi R., Poyer F., Legrand E. i wsp.: Spontaneous and cytokine-evoked production of matrix metalloproteinases by bone manow and peripheral blood pre-B cells in childhood acute lymphoblastic leukaemia. Eur. Cytokine Netw., 2005, 16, 223-232.
15. Poyer F., Coquere B., Pegahi R. i wsp.: Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia. Leuk. Res., 2009, 33. 407-417.
16. Pruijt I.F., Fibbe W.E., Laterveer L. I wsp.: Prevention of interieukin-8- induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc. Natl. Acad. Sci. USA, 1999, 96, 10863-10868.
17. Ribatti D., Marimpietri D., Pastorino F. i wsp.: Angiogenesis in neuroblastoma. Ann. NY Acad. Sci., 2004, 1028, 133-142.
18. Schneider P., Costa O., Legrand E. i wsp.: In vitro secretion of matrix metalloprotease-9 is a prognostic marker in childhood acute lymphoblastic leukemia. Leuk. Res., 2009 (epub ahead of print).
19. Scrideli C.A., Cortez M.A., Yunes J.A. i wsp.: mRNA expression of matrix metalloproteinases (MMPs)2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs)1 and 2 in childhood acute lymphoblastic leukemia: Potential role of TIMP1 as an adverse prognostic factor. Leuk. Res., 2009 (epub ahead of print).
20. Suminoe A., Matsuzaki A., Hattori H. i wsp.: Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of acute lymphoblastic leukemia with organ involvement. Leuk. Res., 2007, 31, 1437-1440.
21. de Veas R.G., Schweigerer L., Medina M.A.: Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in paediatric tumour cells. Effects of tumour cell proliferation modulators on gelatinolytic activity. J. Cancer Res. Clin. Oncol., 1995, 121, 275-278.
22. Ylisimió S., Hoyhty H M., Turpeenniemi-Hujanen T.: Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res., 2000, 20, 1311-1316.